Background: To our knowledge, no previous study or literature review has been performed
about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences,
especially regarding alpha-particle emitting radiopharmaceuticals.
Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the
correctness of the procedures applied , unexpected delayed adverse effects can occur.
In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.
Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed
through clinical examples. The sudden intervention allowed a fast remission of the signs and
symptoms complained by patients treated with Radium-223 dichloride.
Conclusion: The management of adverse effects after radiopharmaceuticals administration as in case
of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.